| 证券代码：002022 | 证券简称：科华生物 公告编号：2026-005 | | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 2026年1月31日 关于产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，上海科华生物工程股份有限公司（以下简称"公司"）全资子公司科 华（西安）生物工程有限公司收到国家药品监督管理局颁发的医疗器械注册证。 具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期 | 适用范围/预期用途 | | --- | --- | --- | --- | --- | | | | | | 产品基于实时荧光PCR检测原理，与配 | | | | | 2026年01月29日 | 套的检测试剂共同使用，在临床上用于 | | 1 | 实时荧光定 | 国械注准 | 至 | 对 来 源 于 人 体 样 本 中 的 靶 核 酸 | | | 量PCR仪 | 20263220249 | | | | | | | 2031年01月28日 | (DNA/RNA)进行定性、定量检测，包 ...

科华生物公告，预计2025年度净利润亏损5.8亿元–7.4亿元，上年同期亏损6.41亿元。报告期内，公司坚 守既定发展战略，深度研判行业发展趋势，持续迭代产品矩阵以强化核心竞争力，积极布局国内外双市 场并推进新业务提质扩容，全力护航企业可持续高质量发展。业绩影响的主要因素有：资产减值计提对 利润产生较大不利影响。行业政策叠加市场竞争加剧，量价齐跌，盈利端承压明显。 ...

Group 1 - The core viewpoint of the news highlights significant projected profit increases for various companies in 2025, driven by rising production and sales in precious metals and advancements in technology sectors [1][3]. Group 2 - Xiaocheng Technology anticipates a net profit increase of 93%-179% year-on-year in 2025, with growth in gold production, sales, and international gold prices [1]. - Hunan Silver expects a net profit increase of 67.88%-126.78% in 2025, supported by rising silver and gold production and sales [3]. - Industrial Fulian projects a 56%-63% year-on-year increase in net profit for Q4 2025, with AI server revenue growth exceeding 50% quarter-on-quarter and over 5.5 times year-on-year [3]. - Keda Xunfei forecasts a net profit increase of 40%-70% in 2025, benefiting from the scaling of artificial intelligence applications [3]. - Albitex anticipates a net profit increase of 100.96% in 2025, primarily due to its focus on aerospace and expansion into the civilian market [3]. - Companies like Hainan Mining and Meixin Sheng are also making strategic acquisitions and investments to enhance their market positions [3].

Group 1: Nipah Virus Detection Products - Wanfu Biology announced the launch of "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" to meet the demand for rapid and accurate testing [2] - Kehua Bio stated that its subsidiary has developed a Nipah virus detection kit to support key prevention and control points such as customs and disease control centers [3] - Zhijiang Biology emphasized the importance of early virus isolation and nucleic acid testing due to the non-specific symptoms in early-stage patients, offering a high-sensitivity detection kit [4] - Capbio has developed a Nipah virus detection kit, providing core technical support for global quarantine and disease control monitoring [4] - Shengxiang Biology offers a dual-platform solution for rapid and accurate detection of Nipah virus, with its detection kit already receiving EU CE certification [4] - Antu Biology provides rapid detection support through its fully automated nucleic acid purification and real-time fluorescent PCR analysis system [4] Group 2: Market Reactions and Clarifications - Some A-share companies clarified their positions, stating they do not have any business related to Nipah virus. Hualan Biological announced it has no vaccine products for Nipah virus [5] - Sely Medical confirmed it currently has no Nipah virus testing reagents or treatment drugs in reserve [6] - Other companies like Weixin Kang and CanSino also stated they do not have related products [7]

凯普生物20cm涨停，智飞生物、万孚生物涨超10%，之江生物、华兰疫苗此前涨停，康希诺、硕世生 物、科华生物涨幅居前。 (本文来自第一财经) ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301363 | 美好医疗 | 32.18 | -5.46% | 18.03万 | 5.96 Z | | 301093 | 不是股份 | 79.99 | -5.17% | 9.73万 | · 7.87亿 | | 688351 | 微电生理 | 24.55 | -5.10% | 9.77万 | 2.43 Z | | 688029 | 南微医学 | 81.25 | -4.96% | 4.46万 | 3.64亿 | | 300753 | 爰朋医疗 | 33.75 | -4.74% | 11.59万 | 3.94亿 | | 688068 | 热景生物 | 147.44 | -4.65% | 2.75万 | 4.05 Z | | 688217 | 睿昂基因 | 31.14 | -4.45% | 1.98万 | 6293.79万 | | 300246 | 宝莱特 | 13.79 | -4.44% | 18.01万 | 2.50亿 | | 688393 | 安必 ...

截至1月26日收盘，猴痘概念上涨3.13%，位居概念板块涨幅第8，板块内，50股上涨，凯普生物、迈克 生物、之江生物等20%涨停，达安基因、科华生物等涨停，万孚生物、智飞生物、百普赛斯等涨幅居 前，分别上涨16.23%、14.87%、12.58%。跌幅居前的有谱尼测试、富祥药业、合富中国等，分别下跌 9.72%、5.51%、5.32%。 资金面上看，今日猴痘概念板块获主力资金净流入15.26亿元，其中，46股获主力资金净流入，6股主力 资金净流入超亿元，净流入资金居首的是智飞生物，今日主力资金净流入2.61亿元，净流入资金居前的 还有众生药业、君实生物、达安基因等，主力资金分别净流入2.23亿元、1.69亿元、1.65亿元。 今日涨跌幅居前的概念板块 | 688575 | 亚辉龙 | 1.73 | 2.31 | 1476.63 | 7.35 | | --- | --- | --- | --- | --- | --- | | 300439 | 美康生 | 5.17 | 7.59 | 1457.59 | 6.07 | | | 物 | | | | | | 300482 | 万孚生 | 16.23 | 15.99 | ...

Group 1 - The Nipah virus outbreak in West Bengal, India, has led to 5 confirmed cases, including healthcare workers, with nearly 100 individuals under home quarantine [1][2] - The virus has a high fatality rate of over 40%, with some reports indicating rates as high as 75%, and there is currently no effective vaccine or treatment available [2][3] - The outbreak has prompted heightened public health alerts globally, with neighboring countries like Thailand and Nepal increasing their screening and quarantine measures for travelers from India [3] Group 2 - The A-share market saw a surge in stocks related to influenza, virus testing, and vaccines, with several companies hitting their daily price limits [1][4] - Companies like Zhijiang Biology and Hualan Vaccine confirmed they have relevant products but currently lack orders from India, while others like Antu Biology and Shuoshi Biology are actively promoting their technical capabilities in response to the outbreak [4][5] - Some vaccine companies, such as Jindike, have stated they do not have any products related to the Nipah virus, indicating a divergence in market reactions among different sectors [5][6]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with notable increases such as Kanglaweishi up over 20% and several others reaching the daily limit of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has prompted a response from local authorities, with nearly a hundred individuals under home quarantine due to the high mortality rate of up to 75% and the absence of a vaccine [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [1] Group 2 - Historical context indicates that Nipah virus outbreaks have previously occurred in Malaysia, Singapore, India, Bangladesh, and the Philippines, resulting in significant fatalities and the culling of millions of pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission rate through contaminated food or direct human-to-human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days, and there are currently no specific vaccines or effective treatments available [2] Group 3 - The stock performance of various biopharmaceutical companies shows substantial year-to-date gains, with Kanglaweishi at 45.10%, Maike Biological at 26.90%, and Kaipu Biological at 34.76% [3] - Other companies such as Zhijiang Biological and Jindike also reported significant increases, with year-to-date growth rates of 26.67% and 18.44% respectively [3] - The overall market trend indicates a strong investor interest in biopharmaceutical stocks amid the health crisis related to the Nipah virus outbreak [1][3]

据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最长 可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 | 代码 | 名称 | 张唱 | 总金额 | 总市值 | 现价 | | --- | --- | --- | --- | --- | --- | | 300463 | 迈克生物 | +20.03% | 7666.6 | 85.86 Z | 14.20 | | 300638 | 凯普生物 | +20.03% | 3.36 Z | 46.87 G | 7.25 | | 688317 | 之江生物 | +20.01% | 3.20 乙 | 49.10 Z | 25.55 | | 301207 | 华兰疫苗 | +20.00% | 5.75 G | 140.3 Z | 23.34 | | 688670 | 金 ...